Novartis (NVS) said that it has appointed Rob Kowalski, Global Head Regulatory Affairs and US Head of Drug Development, as Chief People & Organization Officer. He become a member of the Executive Committee of Novartis, effective September 1, 2021.
Kowalski is a senior drug development and regulatory executive with over 25 years of industry experience. Prior to his current role he has served in various leadership roles in the US and Europe.
Novartis noted that Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the company and almost 8 years in position. Vicki Rawlinson, US Head People & Organization will lead the function ad-interim until Kowalski takes over.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.